220 related articles for article (PubMed ID: 31478593)
1. Clinical outcomes of contemporary drug-eluting stents in patients with and without diabetes mellitus: Multigroup propensity-score analysis using data from stent-specific, multicenter, prospective registries.
Kwon O; Lee JB; Ahn JM; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ;
Catheter Cardiovasc Interv; 2020 Aug; 96(2):243-252. PubMed ID: 31478593
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of different contemporary drug-eluting stents in routine clinical practice: a multigroup propensity score analysis using data from the stent-specific, multicenter, prospective registries.
Kwon O; Kang SH; Lee JB; Ahn JM; Lee CH; Kang DY; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ;
Coron Artery Dis; 2019 Jun; 30(4):255-262. PubMed ID: 30883430
[TBL] [Abstract][Full Text] [Related]
3. Safety and Effectiveness of Second-Generation Drug-Eluting Stents in Patients With Left Main Coronary Artery Disease.
Lee PH; Kwon O; Ahn JM; Lee CH; Kang DY; Lee JB; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ
J Am Coll Cardiol; 2018 Feb; 71(8):832-841. PubMed ID: 29471933
[TBL] [Abstract][Full Text] [Related]
4. Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials.
Kang SH; Chae IH; Park JJ; Lee HS; Kang DY; Hwang SS; Youn TJ; Kim HS
JACC Cardiovasc Interv; 2016 Jun; 9(12):1203-1212. PubMed ID: 27262860
[TBL] [Abstract][Full Text] [Related]
5. Differential cutoff points and clinical impact of stent parameters of various drug-eluting stents for predicting major adverse clinical events: An individual patient data pooled analysis of seven stent-specific registries and 17,068 patients.
Lee CH; Kang DY; Han M; Hur SH; Rha SW; Her SH; Seung KB; Kim KS; Lee PH; Ahn JM; Lee SW; Park SW; Park DW; Park SJ;
Int J Cardiol; 2019 May; 282():17-23. PubMed ID: 30745256
[TBL] [Abstract][Full Text] [Related]
6. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
[TBL] [Abstract][Full Text] [Related]
7. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen), a randomized, controlled, noninferiority trial.
Park KW; Kang SH; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Hur SH; Ryu JK; Lee BR; Park YW; Chae IH; Kim HS;
J Am Coll Cardiol; 2014 Jul; 63(25 Pt A):2805-16. PubMed ID: 24814486
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Safety and Efficacy of Platinum Chromium Everolimus-Eluting Stents in Coronary Artery Disease: 5-Year Results From the PLATINUM Trial.
Kelly CR; Teirstein PS; Meredith IT; Farah B; Dubois CL; Feldman RL; Dens J; Hagiwara N; Rabinowitz A; Carrié D; Pompili V; Bouchard A; Saito S; Allocco DJ; Dawkins KD; Stone GW
JACC Cardiovasc Interv; 2017 Dec; 10(23):2392-2400. PubMed ID: 29217001
[TBL] [Abstract][Full Text] [Related]
9. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization.
Yamaji K; Zanchin T; Zanchin C; Stortecky S; Koskinas KC; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Valgimigli M; Billinger M; Pilgrim T; Heg D; Windecker S; Räber L
Circ Cardiovasc Interv; 2018 Sep; 11(9):e006741. PubMed ID: 30354590
[TBL] [Abstract][Full Text] [Related]
10. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
[TBL] [Abstract][Full Text] [Related]
11. Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT.
Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Danse PW; Schotborgh CE; Scholte M; van Houwelingen KG; Stoel MG; Hartmann M; Tjon Joe Gin RM; Somi S; Linssen GCM; Kok MM; von Birgelen C
JACC Cardiovasc Interv; 2019 Sep; 12(17):1650-1660. PubMed ID: 31422087
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Contemporary Drug-Eluting Stents in Patients Undergoing Complex High-Risk Indicated Procedures.
Jeong YJ; Hyun J; Lee J; Kim JH; Yang Y; Choe K; Lee JS; Park H; Cho SC; Kang DY; Lee PH; Ahn JM; Park DW; Park SJ;
JACC Asia; 2022 Apr; 2(2):182-193. PubMed ID: 36339122
[TBL] [Abstract][Full Text] [Related]
13. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
[TBL] [Abstract][Full Text] [Related]
14. Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial.
van der Heijden LC; Kok MM; Lam MK; Danse PW; Schramm AR; Jessurun GA; Tjon Joe Gin RM; van Houwelingen KG; Hautvast RW; Linssen GC; Sen H; Löwik MM; IJzerman MJ; Doggen CJ; von Birgelen C
Clin Res Cardiol; 2016 Mar; 105(3):206-15. PubMed ID: 26329584
[TBL] [Abstract][Full Text] [Related]
15. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Smits PC; Kaiser C; D'Ascenzo F; Frati G; Mancone M; Genereux P; Stone GW
J Am Coll Cardiol; 2014 Feb; 63(4):299-307. PubMed ID: 24211507
[TBL] [Abstract][Full Text] [Related]
17. Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).
Sen H; Lam MK; Löwik MM; Danse PW; Jessurun GA; van Houwelingen KG; Anthonio RL; Tjon Joe Gin RM; Hautvast RW; Louwerenburg JH; de Man FH; Stoel MG; van der Heijden LC; Linssen GC; IJzerman MJ; Tandjung K; Doggen CJ; von Birgelen C
JACC Cardiovasc Interv; 2015 Jun; 8(7):889-99. PubMed ID: 26003019
[TBL] [Abstract][Full Text] [Related]
18. Two-year clinical outcomes of zotarolimus- and everolimus-eluting durable-polymer-coated stents versus biolimus-eluting biodegradable-polymer-coated stent in patients with acute myocardial infarction with dyslipidemia after percutaneous coronary intervention: data from the KAMIR.
Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
Heart Vessels; 2019 Feb; 34(2):237-250. PubMed ID: 30167772
[TBL] [Abstract][Full Text] [Related]
19. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
Kandzari DE; Koolen JJ; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
JACC Cardiovasc Interv; 2020 Jun; 13(11):1343-1353. PubMed ID: 32499026
[TBL] [Abstract][Full Text] [Related]
20. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
